BNR Burning Rock Biotech Limited
Price Chart
Executive Summary
Burning Rock Biotech reported Q1 2026 revenue of RMB107.9M ($15.6M), down 18.9% YoY, with net loss widening to RMB17.5M from RMB13.5M. All three revenue channels declined, led by a 38.6% drop in pharma R&D services, while gross margin contracted slightly to 72.3%. The company continues to burn cash with operating cash outflow of RMB29.3M in the quarter.
Key Financial Metrics
Actionable Insight
Monitor whether the in-hospital channel can stabilize as management cited a one-off issue at two hospitals; the pharma R&D pipeline recovery is key given the 38.6% segment decline. Cash runway of ~4 quarters at current burn rate suggests potential need for capital raise if trends persist.
Key Facts
- Q1 2026 revenue RMB107.9M ($15.6M), down 18.9% YoY from RMB133.1M
- Net loss widened to RMB17.5M ($2.5M) vs RMB13.5M in Q1 2025
- Pharma R&D services revenue fell 38.6% YoY to RMB22.8M
- Central lab revenue down 15.3% YoY; in-hospital revenue down 8.5% YoY
- Gross margin slipped to 72.3% from 73.2% a year ago
- Operating cash outflow of RMB29.3M ($4.2M) vs RMB23.5M in prior year period
- Cash and restricted cash at RMB448.7M ($65.1M) as of March 31, 2026
Financial Impact
Revenue decline of 18.9% YoY with widening losses and cash burn acceleration
Risk Factors
- Continued revenue contraction across all three channels
- Cash burn accelerating with no path to profitability visible
- Dependence on pharma R&D services which are lumpy and declining
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3308663 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 9, 2026
4d ago
|
Press Release
| $9.66 awaiting T+20 | awaiting T+20 | — | $8.59 (+11.03%) |
|
Jun 9, 2026
4d ago
|
6-K
| $9.66 awaiting T+20 | awaiting T+20 | — | $8.59 (+11.03%) |
|
Apr 28, 2026
6w ago
|
Press Release
| $16.65 $12.17 | ▼ −26.91% | ▼ −32.36% | $8.59 (−48.41%) |
|
Mar 12, 2026
13w ago
|
Press Release
| $22.85 $15.85 | ▼ −30.66% | ▼ −32.63% | $8.59 (−62.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access